Navigation Links
Results From Neurotech's NT-501 Phase 2 Retinitis Pigmentosa Studies Demonstrate Consistent Biological Effect on Photoreceptors
Date:5/28/2009

short 12-month time period," added Dr. Birch.

"We are encouraged with the consistent biological effects of CNTF observed in these two Phase 2 RP studies," commented Ted Danse, President and Chief Executive Officer of Neurotech. "We will continue to follow the patients in these studies and plan to discuss the results and the clinical development path with the Food and Drug Administration (FDA)," added Mr. Danse.

"We are pleased that the NT-501 treatment has shown a positive biological effect on the retina in these two clinical trials, and we are hopeful that vision preservation will be observed when all information is available at the conclusion of the clinical trials," stated Stephen Rose, PhD, Chief Research Officer, Foundation Fighting Blindness. "We are very proud of our long-term support for NT-501 and the innovative ECT technology."

Explants of 25 NT-501 devices from these two studies were prospectively performed between 12 and 24 months following implantation. All have been found to have uniformly healthy, viable cells that continue to produce therapeutic levels of CNTF. This is consistent with data from multiple trials of NT-501 in which, to date, 40 devices have been explanted between 6 and 24 months following implantation and all devices have contained healthy, viable CNTF-producing cells.

"We are very excited about the ability of our ECT platform to deliver a variety of therapeutic factors in a consistent, long-term and well-controlled manner," said Danse. "In addition to these RP studies, we are actively developing NT-501 for geographic atrophy associated with dry AMD, and plan to initiate a Phase 1 study for our second product candidate, NT-503, in wet AMD in the second half of this year. NT-503 inhibits a well-validated target in wet AMD, VEGF, and has the potential to provide a one-time administration for a 12 to 18 month period versus the current wet AMD treatment regimen that requi
'/>"/>

SOURCE Neurotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Gene Network Sciences Announces Broad Cancer Collaboration With UCSF and Initial Results
2. InspireMD Announce the Completion of Enrollment for the MAGICAL Trial (MGuard(TM) in Acute Myocardial Infarction) at EuroPCR 09. Results Will be Presented May 21st by Dr. Dariusz Dudek at the InspireMD Cocktail Reception Debate Chaired by Prof. Martin Le
3. Martek to Announce Second Quarter 2009 Results
4. Cord Blood America to Hold Conference Call on Thursday May 21st at 11 a.m. Eastern Time to Discuss 2009 First Quarter Results and Corporate Developments
5. Resverlogixs Success in Inflammation Program Results in 2 Patents Filed
6. Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business
7. Simcere Pharmaceutical Group Reports Unaudited First Quarter 2009 Results
8. China Biologic Products Announces Strong First Quarter 2009 Results
9. China Dasheng Biotechnology Company Reports Unaudited Third Quarter FY2009 Financial Results
10. China Biologic Products Announces 2009 First Quarter Results Conference Call
11. PharmAthene Reports First Quarter 2009 Financial and Operational Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... 2014  PAREXEL International Corporation (NASDAQ: PRXL ... the Baird Healthcare Conference in New York.  Ingo ... will be making a presentation on PAREXEL and discussing ... 3, 2014. A live webcast of the ... PAREXEL,s website at www.PAREXEL.com in the Upcoming ...
(Date:8/20/2014)... August 20, 2014 Not long ago, ... studies should be performed late in the development cycle ... But current regulatory trends suggest that, like many things ... rise. In recent years, multiple drug sponsors have been ... address specific questions during phase I/II. It’s not only ...
(Date:8/20/2014)... nerves in your ear could improve the health of ... the University of Leeds used a standard TENS machine ... electrical pulses to the tragus, the small raised flap ... of the ear canal. , The stimulation changed the ... reducing the nervous signals that can drive failing hearts ...
(Date:8/20/2014)... GraphDB™ 6.0 from ... the enterprise replication cluster, faster loading speeds, higher ... Elasticsearch. This release happens to coincide with a ... GraphDB™ was formerly known as OWLIM. ... enterprise resilient RDF triplestore will also benefit from ...
Breaking Biology Technology:PAREXEL International To Present At Baird Healthcare Conference 2Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2'Tickling' your ear could be good for your heart 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 2Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 3Ontotext Improves Its RDF Triplestore, GraphDB™ 6.0: Enterprise Resilience, Faster Loading Speeds and Connectors to Full-Text Search Engines Top the List of Enhancements 4
... WALTHAM, Mass. , June 2 Repligen Corporation (Nasdaq: RGEN ... quarter and fiscal year 2010, on Wednesday, June 9th, 2010 , before ... Herlihy , Ph.D., will host a conference call and webcast on the same ... provide a quarterly update on the Company. , ...
... June 2 Vermillion, Inc. (Pink Sheets: VRML), ... Patent Office has issued a Decision to Grant patent ... Cancer" to the Company. The patent claims are directed ... ovarian cancer and to the measurement of the biomarkers ...
... ... The iuvo™ Chemotaxis Assay ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) Plate ... measurements of neutrophil chemotaxis ( http://www.bellbrooklabs.com/iuvo_chemotaxis_assay_plate.html ) in a ... time period of the assay. Designed for use ...
Cached Biology Technology:Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 2Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2010 Financial Results 3Vermillion Announces Issuance of European Patent 2Vermillion Announces Issuance of European Patent 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 2BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 3BellBrook Labs Launches Groundbreaking New Microplate for High Content Chemotaxis Assays in a Stable Gradient 4
(Date:8/20/2014)... Carolina State University researchers have developed methods for electronically ... the electrical signals moths use to control those muscles. ... remotely-controlled moths, or "biobots," for use in emergency response. ... whether we can control the movement of moths for ... says Dr. Alper Bozkurt, an assistant professor of electrical ...
(Date:8/19/2014)... be made to decrease China,s increasing caesarean section rate, ... BJOG: An International Journal of Obstetrics and Gynaecology ... caesarean delivery rates in the world. Of 16 million ... Although the exact rate is not known, the current ... total caesarean rates ranging from 36% to 58%. However, ...
(Date:8/19/2014)... Long-Term Ecological Research and Network-Level Science, , Imagine if ... range of ecosystems was responding to global changes in ... if it coupled multiple decades of information about ecological ... models from dozens of different ecosystem types. , ... Ecological Research (LTER) Network, which will soon celebrate its ...
Breaking Biology News(10 mins):Research paves way for development of cyborg moth 'biobots' 2Is China's 50 percent cesarean section delivery rate too high? 2Is China's 50 percent cesarean section delivery rate too high? 3This week from AGU: Long-term ecological research, predicting cholera outbreaks 2
... Not all trans fats are created equal and it,s time ... reflect this, particularly when it comes to dairy and beef ... the latest edition of Advances in Nutrition , natural ... beef cattle are not detrimental to health and in fact ...
... team of leading marine scientists from around the world ... the deep sea, the Earth,s largest ecosystem. Instead, ... consumers., In a comprehensive analysis published online this week ... fisheries biologists, economists, mathematicians and international policy experts show ...
... fared better than other non-advanced technology exports during the recent ... Foundation (NSF). NSF,s National Center for Science and Engineering ... 2008 to $245 billion in 2009. But this 9 ... ATP exports. ATP exports embody new or leading edge ...
Cached Biology News:Time to reboot thinking on trans fats -- natural trans fats from dairy and beef are good 2Deep-sea fish in deep trouble 2Deep-sea fish in deep trouble 3Recent trends show recession's effect on US advanced technology exports 2
... produced by a patented microwave process which ... consistent, even cell attachment, increased cell growth ... growth uunder difficult conditions, including reduced serum ... a more ecominic alternative to expensive and ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Lines ,High Quality, Functionally-Validated, Ion Channel Cell ... for having a critical role in nerve ... key function in pain, CNS and the ... been investigated in therapeutic areas, such as ...
Biology Products: